[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
|
[2] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
[3] |
杨改标, 李倩, 李璇, 等. 血清AFP, B7-H4联合CP检测对原发性肝癌的诊断价值[J]. 大理大学学报, 2020, 5(10):75-79.
|
[4] |
Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma[J]. Mol Clin Oncol, 2013, 1(4):593-598.
|
[5] |
Waidely E, Al-Yuobi AR, Bashammakh AS, et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J]. Analyst, 2016, 141(1):36-44.
|
[6] |
谈艳芳, 刘利洪, 袁成良. AFP, AFP-L3/AFP, PIVKA-Ⅱ联合检测对原发性肝癌的诊断价值[J]. 检验医学与临床, 2021, 18(20): 2970-2972.
|
[7] |
刘荣静, 冯培, 习浩. PIVKA-Ⅱ联合AFP, AFP-L3诊断原发性肝癌的Meta分析[J]. 检验医学与临床, 2020, 17(12):1648-1650.
|
[8] |
Tayob N, Kanwal F, Alsarraj A, et al. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States[J]. Clin Gastroenterol Hepatol, 2023, 21(2):415-423, e4.
|
[9] |
欧美同学会医师协会肝胆分会, 中国研究型医院学会分子诊断专委会, 中国临床肿瘤学会肝癌专委会, 等. 肝胆肿瘤分子诊断临床应用专家共识[J]. 中华肝胆外科杂志, 2020, 26(2):81-89.
|
[10] |
Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12):1687-1693.
|
[11] |
Jiao C, Cui L, Piao J, et al. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma[J]. J Cancer Res Ther, 2018, 14(6):1239-1244.
|
[12] |
Liu Y, Zhou S, Shi J, et al. c-Myc transactivates GP73 and promotes metastasis of hepatocellular carcinoma cells through GP73-mediated MMP-7 trafficking in a mildly hypoxic microenvironment[J]. Oncogenesis, 2019, 8(10):58.
|
[13] |
Ye QH, Zhu WW, Zhang JB, et al. GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis[J]. Cancer Cell, 2016, 30(3):444-458.
|
[14] |
Liu Y, Zhang X, Zhou S, et al. Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion[J]. J Cell Mol Med, 2019, 23(4):2399-2409.
|
[15] |
Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily[J]. Proc Natl Acad Sci USA, 1997, 94(21):11514-11519.
|
[16] |
Liu X, Chi X, Gong Q, et al. association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma[J]. Plos One, 2015, 10(5):e0127518.
|
[17] |
Myojin Y, Hikita H, Sugiyama M, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production[J]. Gastroenterology, 2021, 160(5):1741-1754, e16.
|
[18] |
Kuang Z, Huang R, Yang Z, et al. Quantitative screening of serum protein biomarkers by reverse phase protein arrays[J]. Oncotarget, 2018, 9(66):32624-32641.
|
[19] |
Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations[J]. Nucleic Acids Res, 2015, 43(Database issue):D146-152.
|
[20] |
李建华, 韩玲. 微小RNA-128对肝癌细胞增殖和凋亡的影响和机制[J]. 中华肝胆外科杂志, 2020, 26(1):57-60.
|
[21] |
胡建军, 郑华荣, 郑耀红. miR-363下调HepG2细胞Mcl-1蛋白的表达并诱导其凋亡[J]. 中国病理生理杂志, 2015, 31(7):1329-1333.
|
[22] |
Wei Y, Chen X, Liang C, et al. A noncoding regulatory RNAs network driven by circ-CDYL acts specifically in the early stages hepatocellular carcinoma[J]. Hepatology, 2020, 71(1):130-147.
|
[23] |
Quinn JJ, Zhang QC, Georgiev P, et al. Rapid evolutionary turnover underlies conserved lncRNA-genome interactions[J]. Genes Dev, 2016, 30(2):191-207.
|
[24] |
赵一鉴, 刘敏, 荆冠军. Lnc-MALAT1在肝癌组织中的表达及对化疗敏感性的影响[J]. 实用肿瘤杂志, 2020, 35(1):53-58.
|
[25] |
Lao Y, Li Q, Li N, et al. Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer[J]. Biochem Biophys Res Commun, 2019, 508(2):339-347.
|
[26] |
Li H, An J, Wu M, et al. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2[J]. Oncotarget, 2015, 6(29):27847-27864.
|
[27] |
Yu Y, Nangia-Makker P, Farhana L, et al. A novel mechanism of lncRNA and miRNA interaction:CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells[J]. Mol Cancer, 2017, 16(1):155.
|
[28] |
Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it[J]. Biochem J, 2004, 382(Pt 1):1-11.
|
[29] |
Steinbichler TB, Dudás J, Riechelmann H, et al. The role of exosomes in cancer metastasis[J]. Semin Cancer Biol, 2017(44): 170-181.
|
[30] |
Zhu C, Su Y, Liu L, et al. Circular RNA hsa_circ_0004277 stimulates malignant phenotype of hepatocellular carcinoma and epithelial-mesenchymal transition of peripheral cells[J]. Front Cell Dev Biol, 2021(8):585565.
|
[31] |
潘韵芝, 马赛, 曹凯悦, 等. 高表达ANXA2肝癌干细胞外泌体对肝癌细胞恶性生物学特性的调控作用[J]. 中国肿瘤, 2019, 28(4):308-314.
|
[32] |
汪晓华, 陈晓军. 肝癌患者外周血外泌体miR-25和miR-141表达水平及联合检测诊断效能研究[J]. 中国卫生检验杂志, 2020, 30(4):472-474.
|
[33] |
Wang H, Hou L, Li A, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma[J]. Biomed Res Int, 2014:864894.
|
[34] |
Ye Q, Ling S, Zheng S, et al. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1):114.
|
[35] |
Pantel K, Alix-Panabières C. Functional studies on viable circulating tumor cells[J]. Clin Chem, 2016, 62(2):328-334.
|
[36] |
Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73(1):422-436.
|
[37] |
Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma[J]. Cancer Res, 2018, 78(16):4731-4744.
|
[38] |
Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy[J]. Clin Cancer Res, 2011, 17(11):3783-3793.
|
[39] |
Li J, Chen L, Zhang X, et al. Detection of circulating tumor cells in hepatocellular carcinoma using antibodies against asialoglycoprotein receptor, carbamoyl phosphate synthetase1and pan-cytokeratin[J]. PLoS One, 2014, 9(4):e96185.
|
[40] |
Liu Z, Guo W, Zhang D, et al. Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry[J]. Sci Rep, 2016(6):39808.
|
[41] |
Jiang P, Xie T, Ding SC, et al. Detection and characterization of jagged ends of double-stranded DNA in plasma[J]. Genome Res, 2020, 30(8):1144-1153.
|
[42] |
Chen L, Abou-Alfa GK, Zheng B, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients[J]. Cell Res, 2021, 31(5):589-592.
|